Durso-Bumpus Debra 4
4 · Blueprint Medicines Corp · Filed Jul 8, 2024
Insider Transaction Report
Form 4
Durso-Bumpus Debra
CHIEF PEOPLE OFFICER
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-07-03−8,817→ 3,850 totalExercise: $54.13Exp: 2030-03-01→ Common Stock (8,817 underlying) - Exercise/Conversion
Common Stock
2024-07-03$54.13/sh+8,817$477,264→ 52,580 total - Sale
Common Stock
2024-07-03$111.29/sh−8,817$981,244→ 43,763 total - Exercise/Conversion
Common Stock
2024-07-05$54.13/sh+3,850$208,401→ 47,613 total - Sale
Common Stock
2024-07-05$111.20/sh−3,850$428,120→ 43,763 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-07-05−3,850→ 0 totalExercise: $54.13Exp: 2030-03-01→ Common Stock (3,850 underlying)
Footnotes (4)
- [F1]Effected pursuant to a trading plan adopted on March 13, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $111.00 to $111.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (3) in this form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $111.00 to $111.34 per share.
- [F4]This option was granted on March 1, 2020 and is fully vested as of the transaction date.